REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Visal Plus Kft. (Hungary)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: VISAL PLUS Kft. Profile Updated: July 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Hungarian Download a sample report

VISAL PLUS Kft is a biotechnology company. The company specializes in research and development of molecular and biotechnology testing systems, including diagnostic prototypes for predicting the effectiveness of chemotherapeutic treatments in non-cellular lung cancer, protein ubicvitination, and small molecular inhibitors of proteins ubikvitilation and ubictine binding for tumor therapy purposes.

Headquarters
Also kikoto sor 11. D. II. em. 217.
Szeged; Csongrad; Postal Code: 6726

Contact Details: Purchase the Visal Plus Kft. report to view the information.

Website: http://www.visalplus.hu

Basic Information
Total Employees:
Purchase the Visal Plus Kft. report to view the information.
Outstanding Shares:
Purchase the Visal Plus Kft. report to view the information.
Registered Capital:
Purchase the Visal Plus Kft. report to view the information.
Financial Auditors:
Purchase the Visal Plus Kft. report to view the information.
Incorporation Date:
December 22, 2008
Key Executives
Purchase this report to view the information.
Managing Director
Ownership Details
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Visal Plus Kft. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency HUF. Absolute financial data is included in the purchased report.
Net sales revenue
136.62%▲
Total operating revenue
136.3%▲
Operating profit (EBIT)
347.53%▲
EBITDA
168.36%▲
Net Profit (Loss) for the Period
638.92%▲
Total assets
16.5%▲
Total equity
33.33%▲
Operating Profit Margin (ROS)
30.88%▲
Net Profit Margin
42.36%▲
Return on Equity (ROE)
20.49%▲
Quick Ratio
0.05%▲
Cash Ratio
0.03%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo